Published online June 4, 2007
PEDIATRICS Vol. 120 No. 1 July 2007, pp. e120-e128 (doi:10.1542/10.1542/peds.2006-1402)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wigal, S. B.
Right arrow Articles by Lerner, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wigal, S. B.
Right arrow Articles by Lerner, M.
Related Collections
Right arrow Therapeutics & Toxicology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Hematologic and Blood Biochemistry Monitoring During Methylphenidate Treatment in Children With Attention-Deficit/Hyperactivity Disorder: 2-Year, Open-Label Study Results

Sharon B. Wigal, PhDa, Timothy E. Wilens, MDb, Mark Wolraich, MDc and Marc Lerner, MDa

a Department of Pediatrics, University of California, Irvine, California
b Psychopharmacology Research Unit, Massachusetts General Hospital, Boston, Massachusetts
c Department of Pediatrics, University of Oklahoma, Oklahoma City, Oklahoma

OBJECTIVES. Patients receiving methylphenidate for the management of attention-deficit/hyperactivity disorder are recommended to receive periodic hematologic monitoring. The objective of this study was to evaluate the long-term effects of methylphenidate treatment on blood biochemistry and hematologic values.

METHODS. This study involved a detailed analysis of changes in hematologic and blood biochemistry values over the course of a 2-year study of once-daily OROS methylphenidate in otherwise healthy children aged 6 to 13 years with attention-deficit/hyperactivity disorder. Routine hematologic and blood biochemistry assessments were performed at baseline, at 6 and 12 months during study treatment, and at the end of the study.

RESULTS. Of the 407 subjects enrolled in the study, 289 completed year 1, and 229 completed 21 of 24 months. No subject was excluded from entry into the study or discontinued from the study because of abnormalities of any of the blood chemistries evaluated. There were no clinically significant changes from baseline in mean values for hematologic or blood biochemistry parameters. For most values, the mean change in value over the course of the study was <5%.

CONCLUSIONS. These longer-term data suggest that chronic therapy with OROS methylphenidate has no clinically significant impact on laboratory values, challenging the necessity of routine hematologic monitoring in otherwise healthy children with attention-deficit/hyperactivity disorder who are treated with methylphenidate.

Key Words: ADHD • hematologic monitoring • blood biochemistry • methylphenidate • stimulant • Concerta

Abbreviations: ADHD—attention-deficit/hyperactivity disorder • ALT—alanine aminotransferase • AST—aspartate aminotransferase • GGT—{gamma}-glutamyltransferase

Accepted Dec 13, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?